Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Michael Grever¹, Leslie Andritsos², Versha Banerji^{3

4}, Jacqueline C Barrientos⁵, Seema Bhat⁶, James S Blachly⁶, Timothy Call⁷, Matthew Cross⁸, Claire Dearden⁸, Judit Demeter⁹, Sasha Dietrich¹⁰, Brunangelo Falini¹¹, Francesco Forconi¹², Douglas E Gladstone¹³, Alessandro Gozzetti¹⁴, Sunil Iyengar⁸, James B Johnston¹⁵, Gunnar Juliusson¹⁶, Eric Kraut⁶, Robert J Kreitman¹⁷, Francesco Lauria¹⁴, Gerard Lozanski¹⁸, Sameer A Parikh⁷, Jae Park¹⁹, Aaron Polliack²⁰, Farhad Ravandi²¹, Tadeusz Robak²², Kerry A Rogers⁶, Alan Saven²³, John F Seymour²⁴, Tamar Tadmor²⁵, Martin S Tallman¹⁹, Constantine S Tam²⁴, Enrico Tiacci¹¹, Xavier Troussard²⁶, Clive Zent²⁷, Thorsten Zenz²⁸, Pier Luigi Zinzani²⁹, Bernhard Wörmann³⁰

Affiliations

¹ Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA. Michael.grever@osumc.edu.
² Division of Hematology Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
³ Department of Internal Medicine & Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
⁴ Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada.
⁵ Department of Medicine, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Feinstein Institute for Medical Research, New York, NY, USA.
⁶ Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA.
⁷ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
⁸ Royal Marsden Hospital, London, UK.
⁹ Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
¹⁰ Department of Hematology, University Hospital, Heidelberg, Germany.
¹¹ Institute of Hematology, Department of Medicine and Surgery, University and Hospital of Perugia, Perugia, Italy.
¹² Cancer Sciences and Haematology Department, University of Southampton Hospital Trust, Southampton, UK.
¹³ Johns Hopkins University, Baltimore, MD, USA.
¹⁴ University of Siena Policlinico S Maria alle Scotte, Siena, Italy.
¹⁵ Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
¹⁶ Stem Cell Centre, Department of Laboratory Medicine, Lund University, and Department of Hematology, Skåne University Hospital, Lund, Sweden.
¹⁷ Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD, USA.
¹⁸ Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA.
¹⁹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²⁰ Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
²¹ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
²² Department of Hematology, Medical University of Lodz, Lodz, Poland.
²³ Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA, USA.
²⁴ Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.
²⁵ Hematology Unit, Bnai-Zion Medical Center and Rappaport Faculty of Medicine, Technion Institute Technology, Haifa, Israel.
²⁶ Department of Hematology, Centre Hospitalier Universitaire Côte de Nacre, Caen, France.
²⁷ James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
²⁸ Department of Medical Oncology and Haematology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
²⁹ IRCCS Azienda Ospedaliero-Universitaria di Bologna and Instituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi, Bologna, Italy.
³⁰ Charité-University Medicine, Berlin, Germany. bernhar.woermann@charite.de.

PMID: 33947938
PMCID: PMC8093591
DOI: 10.1038/s41375-021-01257-7

Review

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Michael Grever et al. Leukemia. 2021 Jul.

. 2021 Jul;35(7):1864-1872.

doi: 10.1038/s41375-021-01257-7. Epub 2021 May 4.

Authors

Affiliations

¹ Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA. Michael.grever@osumc.edu.
² Division of Hematology Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
³ Department of Internal Medicine & Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
⁴ Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada.
⁵ Department of Medicine, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Feinstein Institute for Medical Research, New York, NY, USA.
⁶ Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA.
⁷ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
⁸ Royal Marsden Hospital, London, UK.
⁹ Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
¹⁰ Department of Hematology, University Hospital, Heidelberg, Germany.
¹¹ Institute of Hematology, Department of Medicine and Surgery, University and Hospital of Perugia, Perugia, Italy.
¹² Cancer Sciences and Haematology Department, University of Southampton Hospital Trust, Southampton, UK.
¹³ Johns Hopkins University, Baltimore, MD, USA.
¹⁴ University of Siena Policlinico S Maria alle Scotte, Siena, Italy.
¹⁵ Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
¹⁶ Stem Cell Centre, Department of Laboratory Medicine, Lund University, and Department of Hematology, Skåne University Hospital, Lund, Sweden.
¹⁷ Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD, USA.
¹⁸ Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA.
¹⁹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²⁰ Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
²¹ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
²² Department of Hematology, Medical University of Lodz, Lodz, Poland.
²³ Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA, USA.
²⁴ Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.
²⁵ Hematology Unit, Bnai-Zion Medical Center and Rappaport Faculty of Medicine, Technion Institute Technology, Haifa, Israel.
²⁶ Department of Hematology, Centre Hospitalier Universitaire Côte de Nacre, Caen, France.
²⁷ James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
²⁸ Department of Medical Oncology and Haematology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
²⁹ IRCCS Azienda Ospedaliero-Universitaria di Bologna and Instituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi, Bologna, Italy.
³⁰ Charité-University Medicine, Berlin, Germany. bernhar.woermann@charite.de.

PMID: 33947938
PMCID: PMC8093591
DOI: 10.1038/s41375-021-01257-7

Abstract

Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.

PubMed Disclaimer

Conflict of interest statement

LA: previously provided consultation services for Innate Pharma and AstraZeneca. VB: VB serves on the Advisory Boards of Gilead, Lundbeck, Janssen, AstraZeneca, and Abbvie and has had research funding from CIHR, LLSC, CCMF, Roche, Janssen, Abbvie, and Lundbeck. VB also received fees from BIOGEN for patented compounds unrelated to this study. JCB: research funding: AstraZeneca, Oncternal, TG therapeutics, Pharmacyclics/AbbVie; Advisory Board: AstraZeneca, Pharmacyclics/Abbvie, Beigene, Genentech, Gilead, Innate. SB: served on Advisory board for Pharmacyclics and Janssen, Beigene and AstraZeneca; received honorarium from OncLive; received travel grant from Arqule. JSB: consulting and Advisory Board: AbbVie, AstraZeneca, INNATE Pharma, KITE Pharma; research funding: MingSight Pharmaceuticals: patents and intellectual property: a leukemia diagnostic device (patent pending). Research work is funded by the Royal Marden Cancer Charity. CD: has been an advisor for Medimmune/Innate Pharma (moxetumomab); consulting/Advisory Board for Abbie and Jansen. JD: has participated in advisory committees in Hungary for Novartis, Bristol Myers Squibb, Amicus, Angelini, Pfizer, Amgen, Roche. AG: Advisory Board: Amgen, Takeda. Research funding: Jansenn and Cilag SPA. Honoraria: Abbvie, Jansenn Cilag, Celgene, Amgen, Takeda. Michael Grever: consultant: AstraZeneca, Pharmacyclics, Ascerta, Axio, Inc. Research funding: Hairy Cell Leukemia Foundation for Patient Data Registry; travel expenses: Hairy Cell Leukemia Foundation; Scientific Board Chair: Hairy Cell Leukemia Foundation Scientific Board (no reimbursement); Scientific Honorarium: University of Pittsburgh. SI: Advisory and speaker fees: Gilead and Takeda; Advisory: Beigene; Speaker fees: Janssen, Takeda, and Gilead. RJK: employment: National Institutes of Health and Regional Cancer Care Associates; Honoraria: PlatformQ, OncLive, Cure; research funding: Innate, AstraZeneca, Novartis, Genetech, Pfizer, Teva, Hairy Cell Leukemia Foundation; patents: coinventor for NIH patent for Moxetumomab Pasudotox. SAP: research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which SAP is a principal investigator. SAP has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Innate Pharma, Adaptive Biotechnologies, and AbbVie (he was not personally compensated for his participation). JP: research funding from Genentech, Servier, Takeda, Fate Therapeutics, and Amgen. Consulting fees from Servier, Amgen, AstraZeneca, Innate Pharma, Novartis, Kite Pharma, Takeda, Intellia, and Kura Oncology. FR: Consultancy and Honoraria—Celgene, BMS, Amgen, Astellas, Xencor, Agios, AstraZeneca, Orsenix, Innate Pharma, Syros, Taiho, Novartis; research funding—BMS, Amgen, Xencor, Macrogenics, Orsenix, Abbvie, Taiho, Prelude, Astex. TR: research funding: AstraZeneca, Medimmune, Roche, Janssen, Abbvie, Advisory Board; AstraZeneca, Jassen, Abbvie; travel grant: Roche, Janssen; Honoraria: Abbvie, AstraZeneca, Janssen. KAR: received research funding from Genentech, AbbVie, Janssen, and Novartis all paid to her institution, consulted for Acerta Pharma, AstraZeneca, Innate Pharma, Genentech, AbbVie, and Pharmacyclics, received travel funding from AstraZeneca. AS: consultant and Advisory Boards: AstraZeneca and Innate Pharmaceuticals; Speakers Bureau: AbbVie and Pharmacyclics. JFS: AbbVie, Advisory board, speakers’ bureau, research funding; AstraZeneca, Advisory board; Celgene, Advisory board, speakers’ bureau, research funding, expert testimony; Genentech, Advisory board; Gilead, Advisory Board; Janssen, Advisory board, research funding; Mei Pharma, Advisory board; Morphosys, Advisory Board; Roche, Advisory board, speakers’ bureau, research funding, expert testimony; Sunesis, Advisory board; Takeda, Advisory Board. TT: advisor: Roche, AbbVie, Janssen, Takeda, Gilead, AstraZeneca, Novartis. MST: research funding: AbbVie, Amgen, Biosight, Glycomimetics, Orsenix, Rafael; Advisory Boards: Amgen, Daiichi-Sankyo, Delta Fly Pharma, Innate pharmaceuticals, Jazz, Kahr, Kura, Novartis, Orsenix, Roche, Syros; Royalties: UpToDate. CST: Honoraria from Janssen, AbbVie and Beigene, and his hospital receives research funding from Janssen, AbbVie, and Beigene. ET: consultant for Innate Pharma. Research funding: Roche. Travel cost: Shire. Holder of a patent on the use of mutant BRAF as HCL biomarker. Our research work in HCL is funded by the Hairy Cell Leukemia Foundation, the Leukemia and Lymphoma Society, and the Associazione Italiana Ricerca sul Cancro (AIRC). XT: consultant for Innate Pharma, AstraZeneca; advisor: Abbvie. Clive Zent: funding through the University of Rochester for laboratory research, from Acerta/AstraZeneca and TG Therapeutics, and from the Hairy Cell Leukemia Foundation. TZ: advisor: Roche, AbbVie, Janssen, Takeda, Gilead, AstraZeneca. PLZ: Speakers Bureau: Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therap., Takeda, Roche, Eusapharma, Kyowa Kirin; Advisory Board: Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, TG Therap., Takeda, Roche, Eusapharma, Kyowa Kirin, ADC Therap.; consultant: Verastem, MSD, Eusapharma, Sanofi. The other authors declare no competing interests.

References

1. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a Multicenter Study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–91. doi: 10.1158/2159-8290.CD-20-0422. - DOI - PMC - PubMed
1. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–18. doi: 10.1016/S0140-6736(20)31187-9. - DOI - PMC - PubMed
1. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34:1637–45. doi: 10.1038/s41375-020-0836-7. - DOI - PMC - PubMed
1. Martín-Moro F, Marquet J, Piris M, Michael BM, Sáez AJ, Corona M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190:e16–20. doi: 10.1111/bjh.16801. - DOI - PMC - PubMed
1. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020;10:935–41. doi: 10.1158/2159-8290.CD-20-0516. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Affiliations

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical